Company Updates covers news from Brilliant Blue Biosciences. Research & Industry News highlights relevant developments published by external sources, summarised and attributed to them.
MIT News reports a two-stage process that measures lipid nanoparticle size during production and uses the resulting data to guide processing conditions for RNA-therapy development. The team is pursuing commercialisation through BIZON Labs; no clinical testing is reported.
GBI plans to introduce SmartScale, a service aimed at early-stage developers seeking GMP material for clinical development. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The partners will assess automated manufacture of GenomeFrontier's virus-free CAR T process; the collaboration is Cellares' first with an Asian cell-therapy developer. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Moonwalk Biosciences says new financing of $70 million will support an siRNA pipeline targeting adipose tissue and its discovery platform. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →SynGenSys introduced an expanded synthetic promoter library designed for biomanufacturing applications in CHO cells. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Rznomics says its participation in Lilly Gateway Labs is intended to accelerate discovery and development of RNA therapeutic candidates. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The BaseMap ABE launch offers genome-wide measurements in relevant cells to support off-target characterisation during therapeutic development. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →DNA Script reports an ARPA-H award for a DNA manufacturing effort that incorporates its enzymatic synthesis technology. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The NeX solution builds on Enzene's continuous manufacturing platform and is presented as a transportable biologics production option. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →A new test bed linked to the University of Maryland and NIST will support programmable, automated manufacturing workflows. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The partners are exploring Avenue Biosciences' signal-peptide engineering with Circio's circVec technology to increase protein expression. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The collaboration combines Constellation and autoloMATE to address fragmented manufacturing data and process visibility. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The partners plan to move manufacturing of SBT-77-7101 to Cellares' Cell Shuttle and evaluate automated quality-control testing. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The agency has proposed a registration approach for advanced distributed manufacturers using a central quality hub and multiple production units. This is a regulatory or programme announcement; consult the original notice for the precise scope and status.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Fujifilm's Holly Springs manufacturing site was selected as one of the facilities in the FDA's PreCheck pilot programme. This is a regulatory or programme announcement; consult the original notice for the precise scope and status.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Shilpa has commissioned an integrated site for manufacturing antibody-drug conjugate drug substance under GMP conditions. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →An independent UK centre reports a continuous bioprocess intended to improve productivity and lower costs for advanced-therapy manufacturing. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Their planned workflow combines capillary isoelectric focusing fractionation and mass photometry to examine bispecific antibodies and biosimilars. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The partners will evaluate automated manufacturing for TScan's TSC-101 as that programme moves toward a planned pivotal study. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The companies announced joint development work spanning muscle disease gene therapy and in vivo cell-therapy applications. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Wacker is expanding contract research to include RNA and plasmid construct design alongside its existing RNA, pDNA and LNP formulation activities. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The collaboration covers production and quality control of a personalised progenitor T-cell therapy being developed for blood cancers. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →ParcelBio announced a programmable mRNA platform and $13 million in financing for its emerging therapeutic pipeline. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The collaborators will examine how automation could make cell-therapy production more efficient and scalable. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The companies are moving a candidate toward GMP manufacturing after cell-line development, with technology transfer planned between sites. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The company's newly announced control system emphasises instrument integration and real-time manufacturing oversight. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →GEN reviews the translation of nonviral gene-delivery platforms, including lipid and polymer-based approaches. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The WHO designation focuses on workforce training and technology transfer as manufacturing capacity expands across regions. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The company launched to develop protein amplification technology intended for highly sensitive diagnostic testing. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Artis is bringing Syngoi Technologies to a US hub serving synthetic-DNA development and clinical manufacturing. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Research reporting describes modified LNPs intended to improve delivery of mRNA cargo to lymph nodes. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The companies agreed to co-develop an approach to oral monoclonal-antibody delivery using exosomes derived from goat milk. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Eveo is designed to bring cell selection, activation, gene modification and final formulation into one closed workflow. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →GEN reports an amino-acid formulation approach intended to improve LNP delivery for mRNA and CRISPR cargo. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →GEN reports research linking internal lipid-nanoparticle structure with cargo delivery inside cells. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The acquisition brings InDevR's multiplexing capabilities into SSI Diagnostica's diagnostics and vaccine-development portfolio. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Bracco is extending its lipid-based microbubble technology into collaborations with cell-therapy developers and process teams. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Cellares will support automated manufacturing and release assays for gene-edited haematopoietic stem-cell therapies under development at Stanford Medicine. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Their collaboration covers RNA-interference medicines and includes upfront funding and potential development-linked payments. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →GEN reports development of lipid nanoparticles designed to deliver nucleic-acid cargo to lung and eye tissues. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →City of Hope and Cellares agreed to assess Cell Shuttle and Cell Q for solid-tumour CAR T manufacturing and quality control. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →EirGenix gained access to Transcenta's HiCB technologies, which include continuous perfusion and hybrid continuous purification. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →SMRTS is a “smart” mRNA system that switches therapeutic genes on or off depending on cell type, enabling targeted cancer treatments while expanding the mRNA toolbox for precision medicine applications. The post Engineered mRNA System Delivers SMRTS for Cell-Selective Gene Expression appeared first on GEN - Genetic Engineering and Biotechnology News. The report concerns nonviral delivery, nanocarrier development, formulation, or translation; it does not by itself establish clinical benefit.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The Houston facility expands Avance Biosciences' capacity for functional and potency testing during therapy development. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The companies announced a gene-editing collaboration targeting rare liver diseases, marking Chiesi's entry into gene-editing development. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →A two-step microfluidics system created ternary nano-scale lipopolyplexes, using polymer choice to determine the lipopolyplexes’ structure, which affects vector size and distribution. This overcomes barriers to manufacturing and creates nonviral vectors for efficient DNA delivery. The post Microfluidics-Manufactured Lipopolyplexes Offer Size Consistency appeared first on GEN - Genetic Engineering The report concerns nonviral delivery, nanocarrier development, formulation, or translation; it does not by itself establish clinical benefit.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The agreement supports larger-scale production of RION's platelet-derived exosome therapeutics using the company's manufacturing platform. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The collaborators plan to extend Cell Q, an automated platform for in-process and release testing at commercial manufacturing scale. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →A close partnership between academic institutions, industry, and the FDA is necessary for success in manufacturing personalised treatment. That’s a key message behind a talk at BPI this week, presented by Max Sellman of Aldevron. The post Collaboration Key to First Personalised mRNA-based CRISPR Therapy appeared first on GEN - Genetic Engineering and Biotechnology News. The report concerns nonviral delivery, nanocarrier development, formulation, or translation; it does not by itself establish clinical benefit.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →GEN reports research on a polymer-based alternative to PEG in lipid nanoparticles for mRNA delivery. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Engineered extracellular vesicles that deliver full-length DMD mRNA to skeletal muscle restored dystrophin production and significantly improved muscle strength and function in Duchenne muscular dystrophy models without notable toxicity. The post New mRNA Delivery Platform Restores Muscle Function in DMD Models appeared first on GEN - Genetic Engineering and Biotechnology News. The report concerns nonviral delivery, nanocarrier development, formulation, or translation; it does not by itself establish clinical benefit.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.
Prefer to talk it through? Book a 30-minute discovery call
